Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5 ′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, and 5-fluorouracil

ConclusionRabeprazole does not affect capecitabine pharmacokinetics.

http://link.springer.com/10.1007/s00280-019-03837-y

Source: Cancer Chemotherapy and Pharmacology - May 3, 2019 Category: Cancer & Oncology Source Type: research

More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Eloxatin | Oral Cancer | Proton Pump Inhibitors PPIs | Study | Xeloda